An Institute Devoted to Translational Biomedical Research
Home | Contact | Links | 简体中文版
  About Us Research Graduate Education Cooperation and Exchange Translational Research System Technology Platforms Faculty and Staff Join Us  
Home  »  Faculty and Staff  »  Principal Investigators
Principal Investigators

Faculty and Staff

Principal Investigators
LANG Jingyu
Ph.D., Principal Investigator
Laboratory of Cancer Stem Cell and Targeted Therapy

Research Interests or Current Research Focus
1. To identify appropriate therapeutic targets for treating breast and gastric cancers based on currently available cancer genomics data.
2. To distinguish the molecular basis between the responsive and un-responsive cancer patients using the same anticancer agents.
3. To explore the molecular mechanisms that underlie self-renewal ability and chemo/radio-resistance of cancer stem cells, identify potential therapeutic targets that perturb these processes, and eventually develop appropriate small molecule inhibitors for treating cancer stem cells, especially in breast and gastric cancer.

Major Research Achievement
1. Based on multiple criteria, first identified that Bcl-2 antiapoptotic proteins were responsible for the survival of breast tumor initiating cells/breast cancer stem cells (BCSCs) and co-inhibition of these antiapoptotic proteins was required to optimally kill BCSCs;
2. Developed a novel breast cancer-specific targeting approach, in which targeted expression of BIKDD, a constitutive active mutant of proapoptotic gene BIK, effectively eliminated both BCSCs and non-BCSCs prior to or post paclitaxel treatment;
3. Using systemic approaches such as microarray, identified that Integrin-Rho signal pathway was responsible for the novel anti-metastatic effect of salvicine that is known as a Topoisomerase II inhibitor in Phase II clinical trial in China;
4. Identify and validate the biological functions of several key molecules in tumor initiation and progression and the therapeutic targets of several anti-tumor agents both in vitro and in vivo.

1999-2005: Ph.D., Shanghai Institute of Materia Medica, Chinese Academy of Sciences
1995-1999: B.S., Department of Biology, Nanjing University

Major Academic Appointments
2012-present: Principle Investigator, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences/School of Medicine, Shanghai Jiao Tong University
2012: Research Scientist II, Dana-Farber Cancer Institute/Department of Medical Oncology, Harvard Medical School
2005-2011: Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center

Honors, Certificates, and Academic Society
2013: China National Funds for Excellent Young Scientists
2012: Recipient of the Recruitment Program of Global Experts (Young Program)
2011: MD Anderson Cancer Center Ernst W. Bertner Outstanding Publication Award
2004: AACR-Avon Scholar-in-Training Award
2004: Member of American Association for Cancer Research

Recent Publications

  1. Huang TH, Huo L, Wang YN, Xia W, Wei Y, Chang SS, Chang WC, Fang YF, Chen CT, Lang JY, Tu C, Wang Y, Hsu MC, Kuo HP, Ko HW, Shen J, Lee HH, Lee PC, Wu Y, Chen CH, Hung MC. Epidermal Growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Cancer Cell 2013, 23(6):796-810. (Impact factor 26.9)
  2. Wang Y, Ding Q, Yen CJ, Xia WY, Izzo J, Lang JY, Li CW, Miller S, Wang X, Lee DF, Hsu JL, Hsu JM, Huo L, LaBaff A, Liu DP, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar N, Wang K, Wu Y, Wang H, Ajani, J, Hung MC. The Crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012 Mar 20;21(3):374-87. (impact factor 26.9)
  3. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang QF, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 2011, 20(3):341-356. (Impact factor 26.9)
    Leading Edge Selected: Removing breast cancer’s roots. Cell 2011, 147(2):253.
  4. Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, Huo L, Cheng X, Chen YJ, Li CW, Jeng LB, Hsu JL, Li LY, Tan A, Curley SA, Ellis L, DuBois RA, Hung MC. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. 2011, 121 (11):4526-36 [Epub 2011 Oct 10]. (impact factor 14.2)
  5. Banerjee A, Lang JY, Hung MC, Sengupta K, Banerjee SK, Baksi K, Banerjee DK. Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin. J Biol Chem. 2011, 286(33):29127-29138 [Epub 2011 Jun 15]. (Impact factor 5.3)
  6. Wei Y, Chen YH, Li LY, Lang J, Yeh SP, Shi B, Yang CC, Yang JY, Lin CY, Lai CC, Hung MC. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol. 2011 13(1):87-94. (Impact factor 19.4)
  7. Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, You Y, Lang J, Hung MC, Lin X. CARMA3 is crucial for EGFR-induced activation of NF-kB and tumor progression. Cancer Res. 2011, 71(6):2183-92. (Impact factor 8.2)
  8. Song H, Li CW, Labaff AM, Lim SO, Li LY, Kan SF, Chen Y, Zhang K, Lang J, Xie X, Wang Y, Huo LF, Hsu SC, Chen X, Zhao Y, Hung MC. Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. Biochem Bioph Res Co. 2011 404(1):68-73. (Impact factor 2.6)
  9. Li LY, Dai HY, Yeh FL, Kan SF, Lang J, Hsu JL, Jeng LB, Chen YH, Sher YP, Lin WC, Hung MC. Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy. Oncogene. 2010 30(15):1773-83. (Impact factor 7.4)
  10. Cheng X, Xia W, Yang JY, Hsu JL, Lang JY, Chou CK, Du Y, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cancer Res. 2010 70(19):7684-9. (Impact factor 8.2)
  11. Usami Y, Nakagawa-Goto K, Lang JY, Kim Y Lai CY, Goto M, Sakurai N, Taniguchi M, Akiyama T, Morris-Natschke SL, Bastow KF, Cragg G, Newman DJ, Fujitake M, Takeya K, Hung MC, Lee EY, Lee KH. Antitumor Agents. 282. 2 ’-(R)-O-Acetylglaucarubinone, a Quassinoid from Odyendyea gabonensis As a Potential Anti-Breast and Anti-Ovarian Cancer Agent. J Nat Prod. 2010 73(9):1553-8. (Impact factor 2.9)
  12. Dong Y, Shi Q, Pai HC, Peng CY, Pan SL, Teng CM, Nakagawa-Goto K, Yu D, Liu YN, Wu PC, Bastow KF, Morris-Natschke SL, Brossi A, Lang JY, Hsu JL, Hung MC, Lee EY, Lee KH. Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues. J Med Chem. 2010 53(5):2299-2308. (Impact factor 5.2)
  13. Dong Y, Shi Q, Nakagawa-Goto K, Wu PC, Morris-Natschke SL, Brossi A, Bastow KF, Lang JY, Hung MC, Lee KH. Antitumor agents 270. Novel substituted 6-phenyl-4H-furo [3,2-c]pyran-4-one derivatives as potent and highly selective anti-breast cancer agents. Bioorgan Med Chem. 2010 18(2):803-8. (Impact factor 2.9)
  14. Zhou J, Chen Y, Lang JY, Lu JJ, Ding J. Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling. Mol Cancer Res. 2008 6(2):194-204. (Impact factor 4.4)
  15. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008 10(2):138-48. (Impact factor 19.4)
  16. Xie X, Xia W, Li Z, Kuo HP, Liu Y, Li Z, Ding Q, Zhang S, Spohn B, Yang Y, Wei Y, Lang JY, Evans DB, Chiao PJ, Abbruzzese JL, Hung MC. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell. 2007 12(1):52-65. (Impact factor 26.9)
  17. Lang JY, Chen H, Zhou J, Zhang YX, Zhang XW, Li MH, Lin LP, Zhang JS, Waalkes MP, Ding J. Anti-metastasis effect of salvicine on human breast cancer MDA-MB-435 orthotopic xenograft is closely related to Rho-dependent pathway. Clin Cancer Res. 2005 11(9):3455-64. (Impact factor 7.3)
  18. Tong Y, Zhang X, Zhao W, Zhang Y, Lang J, Shi Y, Tan W, Li M, Zhang Y, Tong L, Lu H, Lin L, Ding J. Anti-angiogenic effects of Shiraiachrome A, a compound isolated from a Chinese folk medicine used to treat rheumatoid arthritis. Eur J Pharmacol. 2004, 494 (2-3): 101-109. (Impact factor 2.7)

Invited reviews, comments and book chapters
Lang JY, Shi Y, Chin YE. Reprogramming Cancer Cells: back to the future. Oncogene 2012, Aug 6. Doi. 10.1038/onc.2012.349 [Epub ahead of print]. (Impact factor 7.4)

Cancer-Specific Promoters. International Application No: PCT/US2007/0852 Publication number: WO/2008/070448. Hung MC, Xie XM, Lang JY. (30% effort)

Copyright 2002-2017 The Institute of Health Sciences, SIBS, CAS / SJTUSM All Rights Reserved
225 South Chongqing Road, Shanghai, 200025 P.R. China Tel: 86-21-63847798 / 54923254 Fax: 86-21-63852579
Shanghai ICP #05033115